Literature DB >> 11959791

Complex regional haemodynamic effects of anandamide in conscious rats.

S M Gardiner1, J E March, P A Kemp, T Bennett.   

Abstract

1. Experiments were carried out in conscious, chronically instrumented, male, Sprague-Dawley rats to delineate the regional haemodynamic effects of the putative endogenous cannabinoid, anandamide, (0.075 - 3 mg kg(-1)), and to dissect some of the mechanisms involved. 2. At all doses of anandamide, there was a significant, short-lived increase in mean arterial blood pressure associated with vasoconstriction in renal, mesenteric and hindquarters vascular beds. 3. The higher doses (2.5 and 3 mg kg(-1)), caused an initial, marked bradycardia accompanied, in some animals, by a fall in arterial blood pressure which preceded the hypertension. In addition, after the higher doses of anandamide, the hindquarters vasoconstriction was followed by vasodilatation. 4. Although some of the effects described above resembled those of 5-HT (25 microg kg(-1)), the bradycardia and hypotensive actions of the latter were abolished by the 5HT(3)-receptor antagonist, azasetron, whereas those of anandamide were generally unaffected. 5. None of the cardiovascular actions of anandamide were influenced by the CB(1)-receptor antagonist, AM 251, but its bradycardic effect was sensitive to atropine, and its hindquarters vasodilator action was suppressed by the beta(2)-adrenoceptor antagonist, ICI 118551. 6. The results differ, in several aspects, from those previously reported in anaesthetized animals, and underscore the important impact anaesthesia can have on responses to anandamide.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959791      PMCID: PMC1573314          DOI: 10.1038/sj.bjp.0704649

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

Review 1.  Endocannabinoids.

Authors:  R Mechoulam; E Fride; V Di Marzo
Journal:  Eur J Pharmacol       Date:  1998-10-16       Impact factor: 4.432

2.  Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat.

Authors:  E A Stein; S A Fuller; W S Edgemond; W B Campbell
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

3.  Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats.

Authors:  K D Lake; B R Martin; G Kunos; K Varga
Journal:  Hypertension       Date:  1997-05       Impact factor: 10.190

4.  Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide.

Authors:  K Varga; K Lake; B R Martin; G Kunos
Journal:  Eur J Pharmacol       Date:  1995-05-24       Impact factor: 4.432

5.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.

Authors:  P M Zygmunt; J Petersson; D A Andersson; H Chuang; M Sørgård; V Di Marzo; D Julius; E D Högestätt
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

6.  Involvement of 5-hydroxytryptamine (5-HT)3 receptor mechanisms in regulation of basal pancreatic secretion in conscious rats.

Authors:  M Masuda; K Miyasaka; A Funakoshi
Journal:  J Auton Nerv Syst       Date:  1997-01-12

7.  Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors.

Authors:  S J Gatley; R Lan; B Pyatt; A N Gifford; N D Volkow; A Makriyannis
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

8.  Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

9.  Mechanism of the hypotensive action of anandamide in anesthetized rats.

Authors:  K Varga; K D Lake; D Huangfu; P G Guyenet; G Kunos
Journal:  Hypertension       Date:  1996-10       Impact factor: 10.190

10.  Endogenous angiotensin II and the reflex response to stimulation of cardiopulmonary serotonin 5HT3 receptors.

Authors:  R Veelken; K F Hilgers; K E Scrogin; J F Mann; R E Schmieder
Journal:  Br J Pharmacol       Date:  1998-12       Impact factor: 8.739

View more
  25 in total

Review 1.  The complexities of the cardiovascular actions of cannabinoids.

Authors:  Michael D Randall; David A Kendall; Saoirse O'Sullivan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

Review 2.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  The cardiovascular actions of anandamide: more targets?

Authors:  Michael D Randall
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

4.  Central and peripheral components of the pressor effect of anandamide in urethane-anaesthetized rats.

Authors:  Grzegorz Kwolek; Agnieszka Zakrzeska; Eberhard Schlicker; Manfred Göthert; Grzegorz Godlewski; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

5.  Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.

Authors:  L Moezi; S A Gaskari; H Liu; S K Baik; A R Dehpour; S S Lee
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

6.  The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure.

Authors:  Anusha Penumarti; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2014-01-15       Impact factor: 4.030

Review 7.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

8.  Factors influencing the regional haemodynamic responses to methanandamide and anandamide in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2009-08-20       Impact factor: 8.739

9.  Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat.

Authors:  P M Hoi; C Visintin; M Okuyama; S M Gardiner; S S Kaup; T Bennett; D Baker; D L Selwood; C R Hiley
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

10.  The group IV afferent neuron expresses multiple receptor alterations in cardiomyopathyic rats: evidence at the cannabinoid CB1 receptor.

Authors:  Maurice A Williams; Scott A Smith; Daniel E O'Brien; Jere H Mitchell; Mary G Garry
Journal:  J Physiol       Date:  2007-12-06       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.